Evidence map›Paper›PMID 22192811›Full record

ArticleMolecular neurodegeneration2011

Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy.

Byung Hee Han, Meng-liang Zhou, Ananth K Vellimana, Eric Milner, David H Kim, Jacob K Greenberg, Wenhua Chu, Robert H Mach, Gregory J Zipfel

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 60 citations in OpenAlex.

  1. Preclinical evaluation of [EJNMMI research · 2026
    Article
  2. Review
  3. AβInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Byung Hee HanDepartment of Neurological Surgery, Washington University School of Medicine, St, Louis, MO 63110, USA. hanh@wudosis.wustl.edu
Meng-liang Zhou
Ananth K Vellimana
Eric Milner
David H Kim
Jacob K Greenberg
Wenhua Chu
Robert H Mach
Gregory J Zipfel
Neurological Surgery · USWashington University in St. Louis · USHope Center for Neurological Disorders · US

Funding

WASHINGTON UNIVERSITY NEUROSURGERY RESIDENT RESEARCH EDUCATION PROGRAMR25NS090978 · NINDS · WASHINGTON UNIVERSITY · PI ZIPFEL, GREGORY J · 2015 to 2023
$2.1M
THE ROLE OF A-BETA SPECIES IN VASCULAR SMOOTH MUSCLE CELL AND CEREBRAL ARTERIOLER01NS071011 · NINDS · WASHINGTON UNIVERSITY · PI ZIPFEL, GREGORY J · 2011 to 2015
$1.6M
NINDS NIH HHS 1R01NS071011NINDS NIH HHS R01 NS071011NINDS NIH HHS R25 NS090978
6 · The paper itself

Abstract

backgroundCerebral amyloid angiopathy (CAA) is characterized by deposition of fibrillar amyloid β (Aβ) within cerebral vessels. It is commonly seen in the elderly and almost universally present in patients with Alzheimer's Disease (AD). In both patient populations, CAA is an independent risk factor for lobar hemorrhage, ischemic stroke, and dementia. To date, definitive diagnosis of CAA requires obtaining pathological tissues via brain biopsy (which is rarely clinically indicated) or at autopsy. Though amyloid tracers labeled with positron-emitting radioligands such as [11C]PIB have shown promise for non-invasive amyloid imaging in AD patients, to date they have been unable to clarify whether the observed amyloid load represents neuritic plaques versus CAA due in large part to the low resolution of PET imaging and the almost equal affinity of these tracers for both vascular and parenchymal amyloid. Therefore, the development of a precise and specific non-invasive technique for diagnosing CAA in live patients is desired.

resultsWe found that the phenoxazine derivative resorufin preferentially bound cerebrovascular amyloid deposits over neuritic plaques in the aged Tg2576 transgenic mouse model of AD/CAA, whereas the congophilic amyloid dye methoxy-X34 bound both cerebrovascular amyloid deposits and neuritic plaques. Similarly, resorufin-positive staining was predominantly noted in fibrillar Aβ-laden vessels in postmortem AD brain tissues. Fluorescent labeling and multi-photon microscopy further revealed that both resorufin- and methoxy-X34-positive staining is colocalized to the vascular smooth muscle (VSMC) layer of vessel segments that have severe disruption of VSMC arrangement, a characteristic feature of CAA. Resorufin also selectively visualized vascular amyloid deposits in live Tg2576 mice when administered topically, though not systemically. Resorufin derivatives with chemical modification at the 7-OH position of resorufin also displayed a marked preferential binding affinity for CAA, but with enhanced lipid solubility that indicates their use as a non-invasive imaging tracer for CAA is feasible.

conclusionsTo our knowledge, resorufin analogs are the fist class of amyloid dye that can discriminate between cerebrovascular and neuritic forms of amyloid. This unique binding selectivity suggests that this class of dye has great potential as a CAA-specific amyloid tracer that will permit non-invasive detection and quantification of CAA in live patients.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCerebral Amyloid AngiopathyHumansMiceMice, TransgenicOxazinesPlaque, AmyloidPositron-Emission TomographyProtein BindingAmyloid beta-PeptidesOxazinesresorufin

Identifiers

PMID22192811
PMCPMC3259047
OpenAlexW2164686418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.